Osimertinib (Tagrisso)
(AstraZeneca) Cmax=6 h (median time);
Vd=986 L Metabolized mainly by CYP3A and
metabolized to two pharmacologically active metabolites,
AZ7550 and AZ5105 80 mg tablet orally once daily;
95% binding Interstitial lung disease associated with osimertinib;
(221)
the incidence of interstitial lung disease associated with osimertinib is unclear due to small sample sizes in published reports
(222)